The CEO's $1.11M open-market purchase at $11.12 is a material vote of confidence from the top executive, especially given the stock's 86% analyst buy rating. The CLO's $398K sale is small and likely routine portfolio management. Traders should watch for upcoming clinical catalysts or partnership announcements that may have motivated the CEO's buy.
KURA drugs
KURA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 24 $12.40entry
- T+1 · 3mo ago +9.60%α +9.28% · $13.59
- T+5 · 3mo ago +2.02%α +1.55% · $12.65
- T+20 · 8w ago −5.40%α −6.70% · $11.73
- T+59 · todayOpen
- T+60 · in 5h Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology CEO Troy Wilson purchased $1.11M of stock on the open market at $11.12/share, while Chief Legal Officer Teresa Brophy sold $398K at $12.63. The CEO's large open-market buy is a strong bullish signal, especially given the company's $1.0B market cap, while the CLO's sale is routine in size and likely liquidity-driven. The net direction is mixed by count but heavily skewed to buying by dollar value and insider seniority.
Key Financial Metrics
Key Facts
- CEO Troy Wilson purchased 100,000 shares for $1.11M at $11.12 on 2026-08-17
- CLO Teresa Brophy sold 31,487 shares for $398K at $12.63 on 2026-08-19
- CEO buy represents ~0.11% of KURA's $1.0B market cap
- CLO sale represents ~0.04% of market cap
- Net insider dollar flow is +$714K (buying dominates by 2.8x)
- 86% of analysts rate the stock Buy or Strong Buy
Financial Impact
CEO invested $1.11M of personal capital at $11.12/share, representing ~0.11% of market cap; CLO sale of $398K is routine
Risk Factors
- CLO sale creates a mixed signal that may confuse some traders
- Biotech stocks are binary, CEO buying does not guarantee clinical trial success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KURA-1787378817615 |
Track record
29 reports on KURA
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers